Literature DB >> 28742204

MiR-144 functions as tumor suppressor by targeting PIM1 in gastric cancer.

K Ren1, Q-Q Liu, Z-F An, D-P Zhang, X-H Chen.   

Abstract

OBJECTIVE: Gastric cancer (GC) is one of the most prevalent types of malignant disease Worldwide. Mounting evidence has demonstrated the involvement of miRNAs in the development of GC. One of these miRNAs, miR-144 has been found aberrantly expressed in a variety of human malignancies. PATIENTS AND METHODS: GC tissues were collected from patients, and the level of miR-144 was determined by qRT-PCR. GC cell lines SGC7901 and AGS were used as model cell lines and the anti-tumor effect of miR-144 in both cells were examined. The level of miR-144 was restored in GC cells using miR-144 mimic. Moreover, the target gene of miR-144 wad identified.
RESULTS: In this study, our results showed that low miR-144 level significantly correlated with lymph node metastasis stage, TNM stage and differentiation degree. In addition, we found that miR-144 acted as a tumor suppressor in GC. Moreover, our findings showed that miR-144 exerted an anti-tumor effect by directly targeting RLIP76.
CONCLUSIONS: miR-144 acts as a tumor suppressor in GC and it is a potential therapeutic target for GC treatment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28742204

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  16 in total

1.  A novel circular RNA hsa_circ_0020123 exerts oncogenic properties through suppression of miR-144 in non-small cell lung cancer.

Authors:  Danhua Qu; Bingdi Yan; Rui Xin; Tiangang Ma
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

2.  Circular RNA 0081146 facilitates the progression of gastric cancer by sponging miR-144 and up-regulating HMGB1.

Authors:  Qihua Xu; Bingling Liao; Sheng Hu; Ying Zhou; Wei Xia
Journal:  Biotechnol Lett       Date:  2021-01-26       Impact factor: 2.461

3.  Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation.

Authors:  Jing Liu; Liguo Feng; Haitao Zhang; Jin Zhang; Yanyan Zhang; Shujing Li; Long Qin; Ziyao Yang; Jianxia Xiong
Journal:  Cancer Biol Ther       Date:  2018-03-26       Impact factor: 4.742

4.  [miR-144-3p Inhibits the Invasion and Metastasis of Lung Adenocarcinoma Cells 
by Targeting IRS1].

Authors:  Jun Bai; Yaqiong Hu; Xinlu Chen; Lin Chen; Liping Zhang; Chonggao Yin; Hongli Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-05-20

5.  miR-144 Potentially Suppresses Proliferation and Migration of Ovarian Cancer Cells by Targeting RUNX1.

Authors:  Shichao Han; Jinming Zhu; Yilei Zhang
Journal:  Med Sci Monit Basic Res       Date:  2018-02-15

6.  MicroRNA-144 inhibits cell proliferation, migration and invasion in human hepatocellular carcinoma by targeting CCNB1.

Authors:  Junsheng Gu; Xiaorui Liu; Juan Li; Yuting He
Journal:  Cancer Cell Int       Date:  2019-01-14       Impact factor: 5.722

7.  Effect of miR-144-5p on the proliferation, migration, invasion and apoptosis of human umbilical vein endothelial cells by targeting RICTOR and its related mechanisms.

Authors:  Wei Fu; Zidong Liu; Jing Zhang; Yuxue Shi; Ruiyao Zhao; Heng Zhao
Journal:  Exp Ther Med       Date:  2019-12-23       Impact factor: 2.447

8.  Analysis of survival and prognosis of 298 gastric adenocarcinoma patients with no distant metastasis.

Authors:  Luguang Liu; Hongbo Hao; Lijuan Zhao; Junxia Hu; Baocai Si
Journal:  Oncol Lett       Date:  2017-10-17       Impact factor: 2.967

9.  MicroRNA-144 mediates chronic inflammation and tumorigenesis in colorectal cancer progression via regulating C-X-C motif chemokine ligand 11.

Authors:  Bin Han; Dan Feng; Xin Yu; Yuanqi Liu; Ming Yang; Fei Luo; Liming Zhou; Fu Liu
Journal:  Exp Ther Med       Date:  2018-07-02       Impact factor: 2.447

10.  Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR / ALK wild-type advanced non-small cell lung cancer.

Authors:  Xiao-Xiao Peng; Ruoying Yu; Xue Wu; Shu-Yu Wu; Can Pi; Zhi-Hong Chen; Xu-Chao Zhang; Cun-Yi Gao; Yang W Shao; Li Liu; Yi-Long Wu; Qing Zhou
Journal:  J Immunother Cancer       Date:  2020-01       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.